Changes in Beneficial Ownership · 4
Replimune Group, Inc.
REPLNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2629507-1_4seq1.xml
Filing details
- Report period
- 2026-11-09
- Issuer
- Replimune Group, Inc.
- Issuer CIK
- 0001737953
- Trading symbol
- REPL
Reporting owner 1
- Name
- SLATTERY JOSEPH P
- Reporting owner CIK
- 0001246530
- Relationship
- Director
- Address
- C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN, MA, 01801
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-11-09 | S · Form 4 | 5,200 | D | 21.80 | 1,467 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Signature 1
- Signed
- /s/ Shawn Glidden, attorney-in-fact
- Date
- 2026-11-10
Company context
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.